InterMune
AcquiredInnovative therapies in pulmonology and fibrotic diseases
- Headquarters
- Palo Alto, California
- Employees
- 201–500
- Founded
- 1995
- Business Model
- B2B
- Website
- intermune.com
About
InterMune was a biotechnology company focused on research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). They developed Pirfenidone, marketed as Esbriet® in the EU and Canada. The company was acquired by Roche.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Aug 2014
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...